CNSP CNS Pharmaceuticals Inc: Rasio total nilai perusahaan marang pendapatan

Logo perusahaan publik cnspharma.com (CNSP)

CNS Pharmaceuticals focuses on developing cutting-edge glioblastoma medications, leveraging its investment capital. Patent protection effectively shields the business from dumping, leaving risks solely to new scientific discoveries. Stable management is precisely executing the clinical trial phases. The company's price-to-sales trajectory reflects the asset's dynamics, where the 0.00 metric serves as the target level.

CNS Pharmaceuticals Inc - Rasio nilai perusahaan marang pendapatan CNSP (periode 23.11.2025 - 20.11.2026)

CNS Pharmaceuticals Inc - rincian analitis lan metrik utama (CNSP)

- rega saham lan konsensus proyeksi valuasi:
- informasi babagan dhuwit lan arus kas:
Analisis wiwitan perusahaan:cnspharma.com CNSP
Sampel barang CNS Pharmaceuticals, Inc.

This indicator compares Enterprise Value (EV) with annual revenue, excluding the impact of debt load to identify pricing anomalies and hidden restructuring risks. For CNS Pharmaceuticals (CNSP), which depends on the outcome of a single clinical trial in the absence of stable sales, the current EV/Sales ratio serves as a marker of speculative overvaluation relative to actual fundamental foundations.